| Literature DB >> 28400193 |
Allan B Dietz1, Eric J Dozois2, Joel G Fletcher3, Greg W Butler4, Darcie Radel4, Amy L Lightner2, Maneesh Dave5, Jessica Friton6, Asha Nair7, Emily T Camilleri8, Amel Dudakovic8, Andre J van Wijnen8, William A Faubion9.
Abstract
In patients with Crohn's disease, perianal fistulas recur frequently, causing substantial morbidity. We performed a 12-patient, 6-month, phase 1 trial to determine whether autologous mesenchymal stem cells, applied in a bioabsorbable matrix, can heal the fistula. Fistula repair was not associated with any serious adverse events related to mesenchymal stem cells or plug placement. At 6 months, 10 of 12 patients (83%) had complete clinical healing and radiographic markers of response. We found placement of mesenchymal stem cell-coated matrix fistula plugs in 12 patients with chronic perianal fistulas to be safe and lead to clinical healing and radiographic response in 10 patients. ClinicalTrials.gov Identifier: NCT01915927.Entities:
Keywords: Cell Therapy; Clinical Trial; IBD; STOMP Trial
Mesh:
Year: 2017 PMID: 28400193 PMCID: PMC5484717 DOI: 10.1053/j.gastro.2017.04.001
Source DB: PubMed Journal: Gastroenterology ISSN: 0016-5085 Impact factor: 22.682